Acadian Asset Management »

Acrivon Therapeutics shares owned by Acadian Asset Management

Quarter-by-quarter ownership of Acrivon Therapeutics (ACRV) shares owned by Acadian Asset Management from 13F filings

Historical chart of Acadian Asset Management investment in Acrivon Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Acrivon Therapeutics held by Acadian Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Acrivon Therapeutics by Acadian Asset Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $1.4M 581k 2.41
2025-09-30 $165k 92k 1.79

More positions owned by Acadian Asset Management

NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Alphabet Cap Stk Cl A (GOOGL)
Meta Platforms Cl A (META)
Amazon (AMZN)
Bk Nova Cad (BNS)
JPMorgan Chase & Co. (JPM)
Toronto Dominion Bk Ont Com New (TD)
Deutsche Bank A G Namen Akt (DB)
Ubs Group SHS (UBS)
Broadcom Ord Shs (AVGO)
Booking Holdings (BKNG)
Citigroup Com New (C)
Telefonaktiebolaget Lm Erics Adr B Sek 10 (ERIC)

View all positions for Acadian Asset Management

Top funds holding Acrivon Therapeutics

RA Capital Management
Sands Capital Ventures
Citadel Advisors
Wellington Management Company
Vanguard Group
Renaissance Technologies
Acadian Asset Management
Marshall Wace
Acorn Capital Advisors
UBS Group
Jane Street
BlackRock
Two Sigma Investments
Geode Capital Management
Millennium Management

View all funds holding Acrivon Therapeutics